Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

Inclusion Criteria:

• Subject with both hypertension and hypercholesterolemia must meet the following (1),and the following (2) or (3):
• (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2,and Subjects with well controlled BP value (BP value < 140/90mmHg at Week 0)
• (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2
• (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3months during the previous 12 months, with LDL-C ≥ 160 mg/dL, LDL-C < 250 mg/dL, andTG < 400 mg/dL at Week -2
• Subject with both angina pectoris and hypercholesterolemia must meet the following (1), and the following (2) or (3):
• (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2,and who meet the following criteria; Subjects with well controlled BP value (BP value < 140/90mmHg at Week 0), and subjects with clinically stable of angina pectoris
• (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2
• (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3months during the previous 12 months, with LDL-C ≥ 160 mg/dL, LDL-C < 250 mg/dL, andTG < 400 mg/dL at Week -2

Exclusion Criteria:

• Subjects who need three or more multi-antihypertensive therapies to achieve the targetBP level or uncontrolled status of hypertension at Week 0 (V1); the target BP level isdefined as systolic blood pressure < 140mmHg and diastolic blood pressure < 90 mmHg.
• Uncontrolled or uncontrollable status of hypercholesterolemia at Week -2; A LDL-C ≥ 160 mg/dL even though Atorvastatine 10 mg has administrated